A Large-Scale Serum Metabolite Panel for Baseline Detection of Alzheimer's Disease

Authors:

***Dany Mukesha [1,2,3], Hüseyin Firat MD PhD [1], Guillaume Sacco [2,3]

Affiliations:

[1]**Firalis SA,** 17 rue du fort, 68330 Huningue, France

[2]**Centre Hospitalier Universitaire de Nice**, France

[3]**Université Côte d'Azur**, INSERM, CNRS, IPMC, Nice, France

***Corresponding Author: dany.mukesha@firalis.com; danymukesha@gmail.com

Manuscript word count:

2526 words

Abstract

INTRODUCTION: Blood-based metabolomic signatures offer promising, non-invasive avenues for Alzheimer's disease (AD) detection. We aimed to identify a serum metabolite panel integrated with *APOE* ε4 status for distinguishing AD from cognitively normal (CN) individuals.

METHODS: Baseline data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) were analyzed for 594 participants (237 AD, 357 CN). High-resolution serum metabolomics (Biocrates MxP® Quant 500) and *APOE* data were used for LASSO-based feature selection, followed by machine learning model training and performance evaluation on a held-out test set.

RESULTS: A panel of 151 metabolites distinguished AD from CN with high accuracy (test-set AUC=0.90). Adding *APOE* to the panel further improved the model performance (AUC=0.91 versus AUC=0.75 for *APOE* alone; $p<0.001$), achieving strong sensitivity (0.92), specificity (0.84), and negative predictive value (0.94).

DISCUSSION: Integrating serum metabolomics with *APOE* enables accurate, non-invasive AD detection and offers a scalable screening approach with strong potential to rule out AD in primary care.

ClinicalTrials.gov Identifier: NCT00106899 and related ADNI phases

Keywords: *Alzheimer disease; metabolomics; serum biomarkers; APOE ε4 genotype; machine learning; lipid metabolism; noninvasive detection; blood-based biomarkers; neuroinflammation; mitochondrial dysfunction.*

1. Introduction

Alzheimer's disease (AD), the leading cause of dementia worldwide, imposes enormous public health challenges. Traditional diagnostic tools, such as cerebrospinal fluid (CSF) biomarkers and amyloid positron emission tomography (PET) scans, offer high sensitivity but are invasive, costly, or inaccessible for routine early screening. In May 2025, the U.S. Food and Drug Administration (FDA) cleared the first blood-based biomarker test for aiding in the diagnosis of AD, marking a significant advancement in non-invasive diagnostics [1,2]. This test, which measures the plasma **pTau217/Aβ1-42 ratio**, provides a more accessible alternative for detecting amyloid pathology in symptomatic adults aged 55 years or older. Building on this, Palmqvist and colleagues [3] released a clinical practice guideline in July 2025 on the use of **blood-based biomarkers** (BBMs) in the diagnostic workup of suspected AD within specialized care settings. The guideline offers brand-agnostic, performance-based recommendations, endorsing BBMs with at least 90% sensitivity and 75% specificity for triaging individuals with objective cognitive impairment or as confirmatory tests in specialized settings. It emphasizes cautious integration, **recommending BBMs primarily for initial triage to identify those needing further evaluation**, while advising against their use in asymptomatic populations or primary care without specialist oversight due to risks of misinterpretation.

These developments align with evolving definitions of AD pathology. According to the 2024 National Institute on Aging-Alzheimer's Association (NIA-AA) criteria, the presence of amyloid process is defined by biomarkers such as **Aβ** or the **Aβ42/40 ratio**, establishing a biological basis for AD even in preclinical stages [4]. However, as articulated by Dubois et al. (2024) [5], AD should be viewed as a clinical-biological construct, requiring both the **presence of symptoms** and **confirmatory biomarkers** for a full diagnosis, rather than relying solely on biological markers in asymptomatic individuals. This distinction is crucial, as not all individuals with amyloid-positive (A+) status exhibit a strong potential to progress to clinical AD; many remain stable or progress slowly, highlighting the need for markers that differentiate early amyloidosis from active, progressing pathology. In this study, metabolomics and with genetic

risk factor offer promising avenues, enabling the identification of biochemical and genetic signature that distinguishes clinically and biomarker-defined AD from cognitively normal individuals at baseline.

Large-scale studies, such as UK Biobank (n ≈ 274,000), have demonstrated that blood-based metabolite profiling, in particular lipoprotein lipids, branched-chain amino acids, and glucose metabolism markers, can predict incident AD with robust areas under the curve (AUCs) of 0.86-0.87 when combined with demographic and cognitive features [6–8]. Metabolomics reflects system-wide biochemical changes, offering the potential to detect early pathophysiological shifts in AD. Multi-omics analyses, integrating metabolomic and genomic data, have identified altered ether lipids, acylcarnitines, and amino acids as key predictors of AD progression [8]. Despite these advances, prior studies have not fully integrated high-resolution metabolomic profiling with genetic risk factors like *APOE* ε4 to develop a validated, non-invasive biomarker panel optimized for accurate AD detection in scalable settings like primary care. In response, we leverage the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort, with standardized biospecimen collection and high-resolution metabolomic data generation via the Biocrates MxP® 500 HR platform. We integrated metabolomic features using robust machine learning pipelines, including least absolute shrinkage and selection operator (LASSO) feature selection and classifiers such as Random Forest and XGBoost, to identify a reproducible serum metabolite signature distinguishing AD from cognitively normal (CN) individuals.

2. Method

Data collection

We analyzed data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), a multicenter longitudinal study designed to develop clinical, imaging, genetic, and biochemical biomarkers for AD. From 2,418 participants across ADNI-1, ADNI-GO, ADNI-2, and ADNI-3 phases, we selected 594 individuals with definitive baseline diagnoses: 237 patients meeting 2024 NIA-AA framework criteria for confirmed AD [9,10] and 357 cognitively normal controls (Clinical Dementia Rating -- Sum of Boxes [CDR-SB] = 0, Mini-Mental State Examination [MMSE] ≥28). Diagnostic validity and group separability were confirmed via cross-domain discriminant analyses. Participants with comorbid neurological or major psychiatric disorders or incomplete metabolomic data were excluded. Demographic characteristics (e.g., age, sex, race) of the study population are summarized in the Results section. The study was approved by institutional review boards at all participating sites, and written informed consent was obtained from all participants. Data is available through the ADNI repository. Further information regarding the study protocol can be found at *ClinicalTrials.gov* under identifier NCT00106899.

Metabolomics processing

Serum samples were analyzed using the Biocrates MxP® Quant 500 high-resolution mass spectrometry platform, quantifying 630 metabolites across lipid, amino acid, and energy metabolism pathways **(Figure 1)**. We implemented a preprocessing pipeline: missing values exceeding 20% prevalence per metabolite were excluded, remaining gaps were imputed using k-nearest neighbors (k=5), and data were normalized using probabilistic quotient normalization to correct for batch effects. Metabolite measurements with coefficients of variation >25% in quality control samples were discarded. The final dataset comprised 623 high-quality metabolites after quality filtering. All metabolites were included in downstream analyses without prioritization of any specific classes.

Feature selection

Three feature sets were evaluated: (1) metabolomic data alone, (2) *APOE* ε4 carrier status, and (3) combined metabolomic + *APOE* genotype data. The dataset was divided into a training set (70% of the cohort) and test set (30%). Feature selection was performed on training set using least absolute shrinkage and selection operator (LASSO) regression with λ (lambda) determined by repeated 5-fold cross-validation **(Supplementary Figure S1)**. Selected features were retained for model training, and top-ranked metabolites were examined for biological relevance to AD pathways in the Results section.

Model training

We trained and compared five machine learning algorithms: LASSO, **partial least squares** (PLS), **random forest**, **extreme gradient boosting** (XGBoost), and **naive bayes**. Models were developed using repeated 5-fold cross-validation (20 repetitions) with stratification by diagnosis and *APOE* status on training set. A held-out test set was used for final evaluation. Potential confounding variables, including age and sex, were adjusted for prior to model building to ensure robust associations between metabolomic profiles and AD status.

Model evalutation

Model performance was primarily assessed using the area under the receiver operating characteristic curve (AUC-ROC), with 95% confidence intervals calculated via 2000 bootstrap replicates. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were reported using the optimal threshold determined by Youden's index from the ROC curve. Pairwise AUC comparisons used the DeLong test [11] and permutation testing [12,13] (1000 iterations) to establish significance against null distributions. All analyses were conducted in R version 4.3.0 (R Foundation for Statistical Computing) using the *pROC* package[14] for ROC analyses and the *caret* package[15] for model development and evaluation.

3. Results

Study population characteristics

There were no statistically significant differences in age, sex, or race between groups. As expected, cognitive performance measures, including Mini-Mental State Examination (MMSE) and Clinical Dementia Rating Scale-Sum of Boxes) CDR-SB scores, demonstrated clear separation between diagnostic groups. The *APOE* ε4 allele was significantly more prevalent among participants with AD, consistent with established genetic risk patterns. Detailed demographic and clinical characteristics are summarized in **Table 1**.

Algorithm performance

Across feature sets, LASSO and PLS algorithms generally outperformed other models **(Figure 2A, Supplementary Table S1)**. Permutation-based null distributions confirmed that the observed classification accuracy could not be attributed to overfitting or random chance **(Figure 2B)**. The plateauing of performance metrics beyond ~150 selected features argued against the need for exhaustive biomarker panels, instead pointing to a finite set of mechanistically interlinked analytes **(Figure 2D)**. Models trained on combined metabolite data + *APOE* genotype yielded higher AUCs compared to using metabolomics data or *APOE* alone **(Figure 3A)**. Of translational relevance, the incremental predictive value of *APOE* status when combined with metabolomics supported a precision medicine approach where genomic context enhances metabolic risk stratification. Confusion matrices revealed balanced classification across groups, with **88% of CN and 91% of AD cases correctly** identified in the combined model, compared to lower accuracy for *APOE*-only predictions (75% CN, 55% AD) **(Figure 3B)**.

Best model results

The LASSO model trained on combined features achieved the best results: mean cross-validated AUC of 0.90 (95% CI: 0.88-0.93 with 2000 stratified bootstrap replicates) on top 151 metabolites (**Supplementary Table S1**). The final test-set reached AUC of 0.91 (95% CI, 0.87-

0.96) with accuracy, recall, precision, and specificity consistently in the high range (**Supplementary Table S2; Figure 3B)**.

Key predictive factors

Chenodeoxycholic acid (CDCA), closely followed by 4-hydroxyproline (*i-4OH-Pro*), tetradecane dioic acid (*DiCA(14:0)*) diacylglycerols (*DG(18:2_18:3)*), stearic acid (*FA(18:0)*) and acylcarnitines (*C3 and C5-M-DC*) were consistently ranked among the most discriminative **(Figure 2C)**. They collectively account for >60% of the feature importance spectrum. While *APOE* alone showed limited predictive power (AUC = 0.75) **(Figure 3A; Figure 3B),** its integration with metabolomics significantly improved model performance (ΔAUC = +0.16 vs. *APOE*-only; $p<0.001$), demonstrating synergistic effects between genetic risk and metabolic pathways.

Metabolite class composition of the discovered panel

To contextualize the biological diversity of metabolite in our panel, with top-151-ranked features, 22 distinct biochemical classes were annotated and identified based on the Biocrates MxP® Quant 500 reference classes (**Supplementary Figure S2**, **Supplementary Table S3**). Lipid subclasses accounted for most selected features. **Triglycerides** were the most represented class, followed closely by **diglycerides** and **phosphatidylcholines**. Several classes of **amino acid-related metabolites** were enriched, including **amino acid derivatives**, **canonical amino acids**, and **biogenic amines**. Importantly, **t4-OH-Pro** and **arginine-related derivatives** are well known to be involved in collagen turnover and nitric oxide signaling, respectively; both implicated in vascular contributions to cognitive impairment. Multiple **sphingolipid subclasses**, including **ceramides** and **hexosylceramides,** were identified, aligning with growing evidence of sphingolipid dysregulation in AD pathophysiology. **Bile acids**, particularly **chenodeoxycholic acid (CDCA)**, ranked among the top individual predictors, showed that metabolic changes in AD are not confined to a single pathway but involve interconnected processes across energy metabolism, neurotransmitter balance, and gut-liver-brain signaling.

4. Discussion

Clinical metabolomic integration

Our study demonstrates that integrating serum metabolomics with *APOE* ε4 status significantly enhances AD detection beyond either modality alone, validating a multi-omics approach for neurodegenerative disease stratification. This aligns with the growing consensus that multi-omics approaches capture complementary biological signals; genetic risk (*APOE*) and downstream metabolic dysregulation (e.g., lipid peroxidation, mitochondrial stress), to improve detection accuracy [16].

The additive effect observed when combining *APOE* with metabolomic features (ΔAUC +0.16 vs. *APOE*-only; **Supplementary Table S2**) suggests synergistic pathophysiological insights: while *APOE* ε4 confers genetic risk, metabolomic signatures capture downstream manifestations of cellular dysregulation (lipid peroxidation, mitochondrial stress) [17–20]. This aligns with emerging frameworks positioning AD as a "network disorder" where genomic susceptibility and metabolic dysfunction co-accelerate pathology [18].

Top predictive features included bile acids, lipid species (sphingomyelins, phosphatidylcholines), branched-chain amino acids and derivatives, and energy metabolism metabolites, were consistent with previously identified metabolic dysregulation in AD [21]. These findings align with prior reports of **mitochondrial dysfunction** and **membrane lipid remodeling** in AD pathogenesis [21]. The lipid dominance aligned with post-mortem studies of AD brain tissue but contrasted with association of *APOE* standalone with amyloid pathology, shows that the model captured distinct, potentially co-occurring disease mechanisms [22,23].

Non-invasive screening potential

The robustness of our serum-based LASSO model (AUC 0.91; NPV 0.94) underscores metabolomics as a scalable, minimally invasive alternative to CSF or PET-based biomarkers [24]. Unlike CSF assays requiring specialized collection or imaging with limited accessibility, our

optimized 151-metabolite panel could be deployed in routine clinical settings. Its high negative predictive value (0.94 with *APOE*) is particularly promising for *ruling out* AD in primary care contexts, potentially reducing unnecessary referrals for costly/invasive tests [24,25].

Model performance comparisons

The consistency of LASSO performance evidenced by narrow confidence intervals, supported its robustness relative to ensemble methods like Random Forest, which showed wider variability in bootstrap replicates (**Supplementary Table S2**). By achieving the highest harmonized performance across sensitivity and specificity in the 151-metabolite feature set, LASSO demonstrated superior discriminative capacity. This contrasted with the pronounced sensitivity-specificity tradeoff observed in PLS, suggesting differential suitability for clinical scenarios prioritizing false-negative minimization [25].

Comparison with previous studies

Compared to prior smaller-scale studies (~100 samples) [19], our large sample and robust platform support broader generalizability. Our AUCs align results from large UK Biobank studies and recent ADNI-based machine learning investigations [26–28]. The identified metabolites (e.g., sphingomyelins, phosphatidylcholines) are consistent with prior ADNI studies implicating lipid metabolism in AD pathogenesis, reinforcing their biological relevance [26–28].

Comparative context for identified blood-based metabolite classes

The broad biochemical spectrum captured by our top-ranked metabolites; spanning lipids, bile acids, and amino acid derivatives; supports prior findings that AD involves complex, multisystem metabolic disturbances. Previous metabolomics studies have similarly reported elevated acylcarnitines and disrupted phospholipid profiles in AD and mild cognitive impairment (MCI) cohorts, though often using narrower panels or untargeted platforms with limited clinical utility [29]. In contrast, our panel provides absolute quantification and regulatory-grade standardization, enhancing translational relevance.

Notably, while CSF biomarkers and PET imaging remain clinical gold standards, they are invasive or costly. In comparison, our blood-based metabolite panel integrated with *APOE* genotype achieved classification performance (AUC=0.91) that is competitive with, and in some contexts exceeds, reported accuracies from imaging-based diagnostics [30]. This supports the growing rationale for metabolomics-driven precision medicine, where metabolic signatures provide complementary, accessible, and biologically informative tools for early AD risk stratification.

5. Limitations

Sample size considerations

Although our sample of 594 is large compared to earlier studies, broader external validation and inclusion of MCI/progression cohorts would strengthen conclusions.

Potential biases

Our cohort is ADNI-based and predominantly white North American; demographic biases may limit generalizability. Batch effects or confounding also remain potential concerns despite rigorous preprocessing. Batch effects or residual confounding (e.g., from education or medication use) remain potential concerns despite rigorous preprocessing. The 151-metabolite panel, while optimized, may risk overfitting due to the high-dimensional nature of metabolomic data. Additionally, model performance was not evaluated across demographic subgroups (e.g., age, sex, race), which could influence biomarker applicability.

6. Future research directions

Expanding sample diversity

Including international, racially diverse cohorts and longitudinal data will enhance external validity and model robustness. Validation in clinical settings, such as primary care, will further confirm the model's utility for non-invasive AD screening.

Advanced algorithm development

Future work could explore transformer-based or graph-theoretical models (e.g. XGML) for explainable biomarker discovery using metabolic network topology. Pathway enrichment analyses could enhance the biological interpretability of the 151-metabolite panel.

Longitudinal studies

Prospective studies tracking conversion from CN or MCI to AD, and longitudinal metabolomic dynamics, will shed light on predictive trajectories and temporal biomarker patterns.

7. Conclusion

This study demonstrates that integrating serum metabolomics with *APOE* ε4 status significantly enhances AD detection, achieving an **AUC of 0.91, a 16% improvement over *APOE*-only models.** The LASSO-optimized 151-metabolite panel, dominated by lipid species (sphingomyelins, phosphatidylcholines) and energy-related metabolites, provides a biologically interpretable and clinically actionable signature of AD-associated metabolic dysfunction. By validating this approach in a large cohort **(>500 participants)** with rigorous permutation testing **(*p*<001)**, we address critical limitations of prior small-scale metabolomic studies while aligning with trends in multi-omics biomarker discovery. Our serum-based model offers a scalable, non-invasive alternative to CSF or PET biomarkers, particularly valuable for primary care settings where its **high negative predictive value (0.94)** can efficiently rule out AD. The synergy between metabolomic features and *APOE* underscores the value of combined genomic-metabolic risk stratification, potentially enabling precision prevention strategies in ε4 carriers. Future validation in diverse cohorts and prospective clinical trials will be critical to confirm the model's generalizability and facilitate its integration into routine AD screening protocols.

8. Acknowledgements

The realization of this project was supported and funded by CombiDiag, HORIZON - MSCA Doctoral Networks 2021 program under grant agreement (GA): 101071485. Data collection/sharing funded by ADNI (NIH Grant U01 AG024904; DOD W81XWH-12-2-0012). ADNI funded by NIA, NIBIB, private sector (full list at adni.loni.usc.edu).

Author Contributions

Dany Mukesha: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Software, Visualization, Writing – Original Draft, Writing – Review & Editing.

Funding/Support

CombiDiag (GA:101071485). Funder had no role in design, analysis, interpretation, or submission. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes

of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclosures

The authors declare no conflicts of interest.

9. Data Sharing Statement

The data supporting the findings of this study are derived from the following resources available in the public domain from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database.

10. Statements and declarations

Ethical considerations: There were no experiments involving animal subjects in this study. The procedures involving experiments on human subjects were done in accord with the ethical standards of the Committee on Human Experimentation of the institution in which the experiments were done or in accord with the Helsinki Declaration of 1975.

Consent to participate: Not applicable

Consent for publication: No data from an individual person (including individual details, images or videos) were used in this article. Not applicable.

Conflicts of interest: All the authors declare no conflict of interest to report with respect to the research, authorship, and/or publication of this article.

Funding statement: All financial and material support for this research has already been

disclosed in the acknowledgements section of the manuscript.

11. Trial registration

Data used in this study were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (ClinicalTrials.gov Identifiers: NCT00106899, NCT01078636, NCT01231971, NCT02854033). ADNI is a multicenter longitudinal study, and its data are publicly available to qualified researchers upon application at https://adni.loni.usc.edu/. No new raw data were generated for this study; analyses were performed on existing ADNI data.

12. Supplemental Materials/ Appendix A

Supplemental Material. In the separate attached document.

13. References

1. Commissioner O of the. FDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease. FDA. May 28, 2025. Accessed August 12, 2025. https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease

2. Hu S, Yu H, Gao J. The pTau217/Aβ1-42 plasma ratio: The first FDA-cleared blood biomarker test for diagnosis of Alzheimer's disease. *Drug Discov Ther*. 2025;19(3):208-209. doi:10.5582/ddt.2025.01055

3. Palmqvist S, Whitson HE, Allen LA, et al. Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. *Alzheimer's & Dementia*. 2025;21(7):e70535. doi:10.1002/alz.70535

4. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup - Jack - 2024 - Alzheimer's & Dementia - Wiley Online Library. Accessed August 12, 2025. https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13859

5. Dubois B, Villain N, Schneider L, et al. Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation. *JAMA Neurol*. 2024;81(12):1304-1311. doi:10.1001/jamaneurol.2024.3770

6. Smirnov DS, Ashton NJ, Blennow K, et al. Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change. *Acta Neuropathol*. 2022;143(4):487-503. doi:10.1007/s00401-022-02408-5

7. Casanova R, Varma S, Simpson B, et al. Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals. *Alzheimer's & Dementia*. 2016;12(7):815-822. doi:10.1016/j.jalz.2015.12.008

8. Oka T, Matsuzawa Y, Tsuneyoshi M, Nakamura Y, Aoshima K, Tsugawa H. Multiomics analysis to explore blood metabolite biomarkers in an Alzheimer's Disease Neuroimaging Initiative cohort. *Sci Rep*. 2024;14(1):6797. doi:10.1038/s41598-024-56837-1

9. Jack Jr. CR, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. *Alzheimer's & Dementia*. 2024;20(8):5143-5169. doi:10.1002/alz.13859

10. Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers Dement*. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018

11. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach. *Biometrics*. 1988;44(3):837-845. doi:10.2307/2531595

12. Bandos AI, Rockette HE, Gur D. A permutation test sensitive to differences in areas for comparing ROC curves from a paired design. *Statist Med*. 2005;24(18):2873-2893. doi:10.1002/sim.2149

13. Efron B, Tibshirani RJ. *An Introduction to the Bootstrap*. 0 ed. Chapman and Hall/CRC; 1994. doi:10.1201/9780429246593

14. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics*. 2011;12(1):77. doi:10.1186/1471-2105-12-77

15. Kuhn M. Building Predictive Models in *R* Using the **caret** Package. *J Stat Soft*. 2008;28(5). doi:10.18637/jss.v028.i05

16. Guo Y, Zou H, Alam MS, Luo S. Integrative Multi-Omics and Multivariate Longitudinal Data Analysis for Dynamic Risk Estimation in Alzheimer's Disease. *Statistics in Medicine*. 2025;44(10-12):e70105. doi:10.1002/sim.70105

17. Cao Y, Meng L, Wang Y, et al. Large-scale prospective serum metabolomic profiling reveals candidate predictive biomarkers for suspected preeclampsia patients. *Sci Rep*. 2025;15(1):4807. doi:10.1038/s41598-025-87905-9

18. Miranda AM, Ashok A, Chan RB, et al. Effects of APOE4 allelic dosage on lipidomic signatures in the entorhinal cortex of aged mice. *Transl Psychiatry*. 2022;12(1):129. doi:10.1038/s41398-022-01881-6

19. Mukesha D, Sarter M, Dubray M, et al. Targeted serum metabolomic profiling and machine learning approach in Alzheimer's disease using the Alzheimer's disease diagnostics clinical study (ADDIA) cohort. *J Alzheimers Dis*. 2025;108(2):824-833. doi:10.1177/13872877251378653

20. Mukesha D, Sarter M, Dubray M, et al. Metabolomic Signatures and Machine Learning Models for Distinguishing Alzheimer's Disease and Dementia with Lewy Bodies. *Alzheimer's & Dementia*. 2025;21(S9):e110610. doi:10.1002/alz70863_110610

21. Toledo JB, Arnold M, Kastenmüuller G, et al. Metabolic network failures in Alzheimer's disease: A biochemical road map. *Alzheimers Dement*. 2017;13(9):965-984. doi:10.1016/j.jalz.2017.01.020

22. Odenkirk MT, Zheng X, Kyle JE, et al. Deciphering ApoE Genotype-Driven Proteomic and Lipidomic Alterations in Alzheimer's Disease Across Distinct Brain Regions. *J Proteome Res*. 2024;23(8):2970-2985. doi:10.1021/acs.jproteome.3c00604

23. Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer's Disease: Advances in Genetics, Pathophysiology, and Therapeutic Approaches. *Lancet Neurol*. 2021;20(1):68-80. doi:10.1016/S1474-4422(20)30412-9

24. Recommendations for sample selection, collection and preparation for NMR-based metabolomics studies of blood | Metabolomics. Accessed July 28, 2025. https://link.springer.com/article/10.1007/s11306-025-02259-7

25. Hajian-Tilaki K. Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation. *Caspian J Intern Med*. 2013;4(2):627-635. Accessed July 28, 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755824/

26. Gianattasio KZ, Bennett EE, Wei J, et al. Generalizability of findings from a clinical sample to a community-based sample: A comparison of ADNI and ARIC. *Alzheimers Dement*. 2021;17(8):1265-1276. doi:10.1002/alz.12293

27. Capó M, Vitali S, Athanasiou G, et al. UK Biobank MRI data can power the development of generalizable brain clocks: A study of standard ML/DL methodologies and performance analysis on external databases. *NeuroImage*. 2025;308:121064. doi:10.1016/j.neuroimage.2025.121064

28. Zhang X, Hu W, Wang Y, et al. Plasma metabolomic profiles of dementia: a prospective study of 110,655 participants in the UK Biobank. *BMC Med*. 2022;20:252. doi:10.1186/s12916-022-02449-3

29. Shao Y, Ouyang Y, Li T, et al. Alteration of Metabolic Profile and Potential Biomarkers in the Plasma of Alzheimer's Disease. *Aging and disease*. 2020;11(6):1459. doi:10.14336/AD.2020.0217

30. Perron J, Scramstad C, Ko JH. Brain metabolic imaging-based model identifies cognitive stability in prodromal Alzheimer's disease. *Sci Rep*. 2025;15(1):17187. doi:10.1038/s41598-025-02039-2

14. Tables

Table 1. Cohort description.

Baseline Characteristics	**Total** (n=594)	**AD** (n=237)	**CN** (n=357)	**P-value**	**Confidence Interval (CI)**
Sex No. (%)					
Female	277 (47%)	105 (44%)	172 (48%)	0.354†	[-0.043, 0.12]
Age					
Mean ± SD	75 ± 6.6	75 ± 7.7	75 ± 5.8		
Median [Q1-Q3]	74 [71-79]	76 [71-80]	74 [71-78]	0.569‡	[-0.82, 1.5]
Min-Max	55-91	55-91	56-89		
***APOE* ε4 allele (%)**					
0	335 (56%)	78 (33%)	257 (72%)		
1	202 (34%)	112 (47%)	90 (25%)	<0.001†	[0.45, 0.67]
2	57 (10%)	47 (20%)	10 (3%)		
MMSE score					
Mean ± SD	27 ± 3.2	23 ± 2	29 ± 1.1		
Median [Q1-Q3]	28 [24-30]	23 [22-25]	29 [29-30]	<0.001‡	[5.5, 6.1]
Min-Max	19-30	19-27	28-30		
CDR-SB score					
Mean ± SD	1.7 ± 2.3	4.3 ± 1.6	0 ± 0	<0.001‡	[4.1, 4.5]
Median [Q1-Q3]	[0-4]	[3.5-5]	[0-0]		
Min-Max	0-10	1-10	0-0		
Education Level (%)					
College+	375 (63%)	132 (56%)	243 (68%)	<0.001†	
< High School	23 (4%)	16 (7%)	7 (2%)		
High School	70 (12%)	39 (16%)	31 (9%)		
Some College	126 (21%)	50 (21%)	76 (21%)		
Race					
White	543 (91%)	222 (94%)	321 (90%)		
Asian	12 (2%)	4 (2%)	8 (2%)		
More than one	5 (1%)	3 (1%)	2 (1%)	0.256†	
Black	33 (6%)	8 (3%)	25 (7%)		
Am-Indian/Alaskan	1 (0%)	0 (0%)	1 (0%)		

†Pearson's chi-squared test; ‡Welch's two-sample t-test. **Abbreviations:** AD, Alzheimer disease; APOE, apolipoprotein E; CDR-SB, Clinical Dementia Rating Scale-Sum of Boxes; CN, cognitively normal; Q1-Q3, interquartile range; MMSE, Mini-Mental State Examination; SD, standard deviation.

Demographic and clinical characteristics of participants with **AD** (n=237) and **CN** (n=357) at baseline. Categorical variables (e.g., **sex**, ***APOE* ε4** allele status) were compared using *Pearson χ^2 tests*. Continuous variables (e.g., **age**, **MMSE**, and **CDR-SB** scores) were compared using *Welch t tests*. Data are presented as **No. (%)**, **mean (SD)**, **median [interquartile range]**, or **range (min-max;** Q1-Q3**)**, as appropriate. *Confidence intervals (CIs)* for between-group differences are reported for proportions and means; CIs for proportions were derived using the

Wald method, and CIs for means were based on the *t-distribution*. Education level categorized by years: <12 = "< High School", 12 = "High School", 13–15 = "Some College", ≥16 = "College+".

15. Figure legends



<u>Figure 1.</u> From serum metabolomics patterns to predictive models for accurate detection of AD. The study analyzed metabolomic profiles from **594 participants (AD vs. CN) in the ADNI cohort,** measuring **up to 630 serum metabolites**. Machine learning was applied to develop predictive models, with performance evaluated using **AUC (area under the curve)** to assess diagnostic accuracy for baseline AD detection. The goal was to derive a highly accurate metabolic signature capable of distinguishing AD from CN individuals at baseline. The workflow highlights the potential of **systems-level metabolomics** combined with **predictive modeling** to uncover reproducible biomarkers for AD, addressing the need for **non-invasive, scalable screening tools**.



<u>Figure 2</u>. Model performance and metabolite importance in predictive analysis.

(A) ROC curves comparing the performance of machine learning models (LASSO, PLS, XGBoost, Random Forest, Naive Bayes) on the test set, with LASSO and PLS showing the highest AUC (0.89). **(B)** Permutation test with shuffling of training labels only, evaluated on an untouched test set, results confirming the robustness of the LASSO model (actual AUC = 0.89). **(C)** Bar plot of the top 25 metabolites ranked by importance scores from LASSO, highlighting key biomarkers such as CDCA and t4-OH-Pro. **(D)** Relationship between the number of metabolites and model performance (AUC), with the optimal subset (151 metabolites) achieving an AUC of 0.9.



<u>Figure 3.</u> Performance comparison machine learning (ML) models with and without *APOE* in AD Classification.

(A) ROC curves comparing LASSO models trained with metabolites only (AUC = 0.90), metabolites + *APOE* (AUC = 0.91), and *APOE* alone (AUC = 0.75) for binary classification of AD vs. cognitively normal (CN) participants. The optimal model (m=151 features) demonstrates improved performance when *APOE* is combined with metabolomic data **(B)** Confusion matrices and **(C)** performance metrics (sensitivity, specificity, precision, accuracy) for each model variant. The LASSO model with *APOE* achieves the highest balanced accuracy

The END.